Free Trial
NASDAQ:VERV

Verve Therapeutics Q3 2023 Earnings Report

Verve Therapeutics logo
$11.13 0.00 (0.00%)
As of 07/25/2025

Verve Therapeutics EPS Results

Actual EPS
-$0.72
Consensus EPS
-$0.90
Beat/Miss
Beat by +$0.18
One Year Ago EPS
N/A

Verve Therapeutics Revenue Results

Actual Revenue
$3.10 million
Expected Revenue
$0.96 million
Beat/Miss
Beat by +$2.14 million
YoY Revenue Growth
+244.40%

Verve Therapeutics Announcement Details

Quarter
Q3 2023
Time
Before Market Opens
Conference Call Date
Tuesday, November 7, 2023
Conference Call Time
1:33PM ET

Upcoming Earnings

Verve Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Monday, August 11, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Verve Therapeutics Earnings Headlines

Verve Therapeutics Announces Merger and Nasdaq Delisting
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Verve Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verve Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verve Therapeutics and other key companies, straight to your email.

About Verve Therapeutics

Verve Therapeutics (NASDAQ:VERV), a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

View Verve Therapeutics Profile

More Earnings Resources from MarketBeat